Date

Tuesday 10, September 2019

Chairs

Thomas Huber (Novartis, Switzerland)
Stefan Weigand (Roche, Switzerland)
Renè Assenberg (Janssen Biologics, Netherlands)

Abstract:

Disruptive innovations are driving future biotherapeutics to become more personalized, cost-effective and efficacious. The biotherapeutics are shifting from classical monoclonal antibodies towards more complex modalities, such as engineered antibodies, multi-specific antibodies, cell and gene therapies. The 2019 biotherapeutics forum discusses technology trends and developments required to progress current and future drug modalities from concepts to the market.